Nautilus Advisors’s AbbVie ABBV Stock Holding History

Nautilus Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.97M	Buy	7,519 +28	+0.4%	+$7.18K	1.19%	19
2026 Q2	$1.86M	Sell	7,491 -910	-11%	-$196K	1.1%	20
2026 Q1	$1.83M	Sell	8,401 -147	-2%	-$32.6K	1.25%	20
2025 Q4	$1.95M	Sell	8,548 -96	-1%	-$21.9K	1.28%	18
2025 Q3	$2M	Buy	8,644 +317	+4%	+$64.6K	1.35%	16
2025 Q2	$1.55M	Buy	8,327 +1,065	+15%	+$198K	1.13%	20
2025 Q1	$1.52M	Buy	7,262 +2	+0%	+$389	1.26%	15
2024 Q4	$1.29M	Buy	+7,260	New	+$1.33M	1.03%	22

Other funds holding ABBV

HCM

Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return

FWCM

Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return

MSV

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Nautilus Advisors's ABBV Position: Q3 2026 in Review

Nautilus Advisors increased its AbbVie (ABBV) stake by 0.37% in Q3 2026, buying an estimated $7.18K and bringing the position to 7,519 shares worth $1.97M. The position accounts for 1.19% of the portfolio, ranked #19.

Nautilus Advisors first reported a position in ABBV in Q4 2024 and has held it in 8 quarters since. The position peaked at $2M in Q3 2025. 246 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Nautilus Advisors held 7,519 shares of AbbVie worth $1.97M as of Q3 2026.
Nautilus Advisors bought 28 AbbVie shares in Q3 2026, an estimated $7.18K.
AbbVie made up 1.19% of Nautilus Advisors's portfolio in Q3 2026, its #19 holding.
Nautilus Advisors first reported a position in AbbVie in Q4 2024 and has held it in 8 quarters since.
Nautilus Advisors's AbbVie position peaked at $2M in Q3 2025.
246 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Nautilus Advisors's 13F filing for Q3 2026, filed 7 Oct 2026.